Goldenwell Biotech, Inc.
GWLL · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $48 | $16 |
| % Growth | -94.1% | -95.1% | 199.4% | – |
| Cost of Goods Sold | $0 | $1 | $23 | $8 |
| Gross Profit | $0 | $1 | $25 | $8 |
| % Margin | 46% | 47.4% | 52.7% | 52.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $123 | $118 | $1,010 | $127 |
| SG&A Expenses | $123 | $118 | $1,010 | $127 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $123 | $118 | $1,010 | $127 |
| Operating Income | -$123 | -$117 | -$985 | -$118 |
| % Margin | -88,559.7% | -4,995.5% | -2,060.9% | -740.7% |
| Other Income/Exp. Net | -$8 | $0 | $0 | $1 |
| Pre-Tax Income | -$131 | -$117 | -$985 | -$117 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$131 | -$117 | -$985 | -$117 |
| % Margin | -94,602.9% | -4,995.5% | -2,060.9% | -732.6% |
| EPS | -0.001 | -0.001 | -0.01 | -0.001 |
| % Growth | -8.3% | 88.2% | -684.6% | – |
| EPS Diluted | -0.001 | -0.001 | -0.01 | -0.001 |
| Weighted Avg Shares Out | 99,000 | 96,448 | 96,433 | 91,322 |
| Weighted Avg Shares Out Dil | 99,000 | 96,433 | 96,433 | 91,322 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $8 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $117 | $985 | $118 |
| EBITDA | -$123 | $0 | $0 | $0 |
| % Margin | -88,559.7% | 0% | 0% | 0% |